Mon, Mar 2, 2015, 12:29 PM EST - U.S. Markets close in 3 hrs 31 mins


% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

baltbearfinance 8 posts  |  Last Activity: Feb 8, 2015 7:10 PM Member since: Apr 20, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • baltbearfinance by baltbearfinance Dec 24, 2014 1:32 PM Flag

    Climb on board!

  • Is this correct? If so I'm out.

  • Reply to

    BTX subsidiary and GE strike deal

    by btimnextmicrosoft Dec 15, 2014 1:50 PM
    baltbearfinance baltbearfinance Jan 9, 2015 9:35 PM Flag

    Upside as a result minimal, with BTX ip I'd say we are in for a continual uptrend throughout 2015.

  • baltbearfinance by baltbearfinance Feb 4, 2015 3:42 PM Flag

    Serious answers appreciated.

  • Reply to

    Two Milestones to be announced in Dec

    by btimnextmicrosoft Dec 8, 2014 3:05 PM
    baltbearfinance baltbearfinance Dec 8, 2014 3:27 PM Flag

    News Tuesday?

  • Reply to

    GE presenter speaking now

    by headsupeyesclosed Dec 15, 2014 3:33 PM
    baltbearfinance baltbearfinance Jan 9, 2015 12:26 PM Flag

    BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
    December 15, 2014

    ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. (“ESI”) and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI’s stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.

    As the worldwide pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, access to more biologically relevant and predictive cell models is becoming increasingly important. The agreement provides ESI with access to additional intellectual property and hence the ability to further expand its product portfolio bringing the benefits of stem cell derived assays and models to pharmaceutical and cell science research.

    “The mission of BioTime’s ESI BIO division, which includes ES Cell International, is to sell high quality tools of regenerative medicine to the research product markets, and this licensing agreement will allow the company to provide superior products for clinical research and drug testing,” said Jeffrey Janus, ES Cell International’s CEO and BioTime’s VP of Sales and Marketing. “The ESI BIO business has the potential to generate near-term revenues for BioTime while simultaneously placing clinical grade cells, injectable matrices, and related components of a wide array of potential regenerative therapies into the hands of potential collaborators.”

  • baltbearfinance baltbearfinance Feb 4, 2015 2:50 PM Flag

    GEHC and BTX have a partnership for ESI cell lines for toxicity and assay use, nothing to do with cancer.
    OncoCyte as far as I know has a foot in the door with Weill Cornell and some high profile cancer institutions in the EU, so you might want to look closer at their affiliations.

  • Reply to

    News recap for last two months

    by ipstissueface Feb 6, 2015 3:44 PM
    baltbearfinance baltbearfinance Feb 6, 2015 4:58 PM Flag

    Lookin good! Biotime a leader in stem cell, cancer and genome big data sector that are about merge leaving us the cream of the crop.

0.00010.0000(0.00%)11:54 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.